Early drug trial hopes to tame rare leukemia
NCT ID NCT05316116
Summary
This small, early-stage study tested the safety and effectiveness of a drug called siltuximab for adults with a rare blood cancer called large granular lymphocytic leukemia (LGLL). The goal was to see if the drug could reduce cancer cells and improve blood counts. The study was terminated early and only included 6 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE GRANULAR LYMPHOCYTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.